1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. China >
  5. JW Therapeutics Acquires Syracuse Biopharma

M&A Deal Summary

JW Therapeutics Acquires Syracuse Biopharma

On July 20, 2020, JW Therapeutics acquired life science company Syracuse Biopharma

Acquisition Highlights
  • This is JW Therapeutics’ 1st transaction in the Life Science sector.
  • This is JW Therapeutics’ 1st transaction in China.

M&A Deal Summary
Date 2020-07-20
Target Syracuse Biopharma
Sector Life Science
Buyer(s) JW Therapeutics
Deal Type Add-on Acquisition

Target

Syracuse Biopharma

China
Syracuse Biopharma (Hong Kong) Ltd. commercialize Eureka’s proprietary TCR-mimic and antibody-TCR ARTEMIS® programs in China and the ASEAN countries. Syracuse’s clinical programs include Eureka’s anti-AFP ARTEMIS® program for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer, which is currently in a Phase I/II clinical trial in the United States. Syracuse Biopharma was founded in 2017 and is based in Hong Kong.

Search 214,557 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

JW Therapeutics

Shanghai, China
Category Company
Sector Life Science
DESCRIPTION

JW Therapeutics is a clinical-stage biopharmaceutical company focusing on the development, transformation and promotion of leading cell immunotherapy. JW Therapeutics is based in Shanghai, China.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: China M&A 1 of 1
Year: 2020 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal